[Cancer Management and Research] Secondary cancer risk following radiotherapy is an increasingly important topic in clinical oncology with impact on treatment decision making and on patient management.
Radiogenomics is maturing into a predictor of patients' likelihood of experiencing radiotoxicities and late radiation effects.
Psychosocial decline occurs in an estimated one-third of patients undergoing radiotherapy for cancer. These declines may sometimes be ameliorated by vigilant recognition of the need to refer patients for psychosocial support interventions.
High-dose-rate (HDR) brachytherapy is typically used as a dose-escalating boost for external beam radiotherapy for prostate cancer; however, some researchers believe it might be close to graduating to a viable monotherapy.
Some patients undergoing radiotherapy for cancers of the head, neck, and brain are at risk for endocrinopathies. This article reviews the risks, detection, and management of radiotherapy-induced hypopituitarism.
What is the best approach to learning more about the field of Radiation Oncology?
Is there a difference in dosing (1 hour prior to radiotherapy vs bedtime) with temozolomide plus radiotherapy for glioblastoma multiforme?
Is combination therapy of imatinib (Gleevec) and radiotherapy safe?
Sexual dysfunction is a common and distressing side effect of prostate cancer treatment. Two new reports from randomized clinical trials offer mixed results for adjuvant pharmacotherapy intended to prevent erectile dysfunction in men undergoing radiotherapy for prostate cancer.
ANAHEIM, CALIFORNIA—Among oropharyngeal patients receiving radiotherapy, gabapentin improved pain management and reduced weight loss, which potentially prevents the need for placement of a gastrostomy tube, according to a study presented at the Oncology Nursing Society (ONS) 39th Annual Congress.
More than a third of women who should receive radiation subsequent to mastectomy are actually undergoing the recommended postmastectomy radiation therapy (PMRT), according to a new study.
A new study has identified three genes that combined enable a lethal form of brain cancer to recur and progress after radiation therapy.
A novel radio-guided surgery technique could quickly and effectively identify residual cancer cells during brain tumor surgery, reducing radiation exposure for both patients and surgeons.
Radiotherapy can be avoided by older women with breast cancer without a compromise to their safety, according to a recent study.
Significant benefits of exercise regimen in reducing the effect of percutaneous endoscopic gastrostomy placement on swallowing function for patients with head and neck cancer.
European researchers explore using patient-reported outcome tool to monitor radiotherapy side effects
Researchers have developed a tool to monitor the effects, including fatigue and inflammation, commonly associated with the radiotherapy used to treat lung cancer.
The addition of radiation treatment to hormone therapy reduced more cancer deaths among older men locally advanced prostate cancer, compared to hormone therapy alone.
Findings in a quasi-experimental study of Taiwanese women with early-stage breast cancer showed the potential for exercise to reduce fatigue in women undergoing radiotherapy.
Stereotactic body radiation therapy (SBRT) plus chemotherapy improves survival among patients with stage 4 lung cancer
Combining stereotactic body radiation therapy (SBRT) with a specific chemotherapy regimen more than doubled survival rates for certain patients with stage 4 lung cancer, according to recent research data.
Radiation makes a stem cell lose its stem-ness, making stem cells damaged by radiation differentiate into other cells that can no longer survive forever.
- Women educated on overdiagnsosis are less likely to want mammogram
- New treatment method shrinks ovarian cancer tumors and improves chemotherapy effectiveness
- Epigenetic signatures differentiate triple negative breast cancers
- Novel drug approved for multiple myeloma
- Radiation therapy used most often for prostate cancer regardless of decision-making factors
- Farydak (panobinostat) now FDA-approved for multiple myeloma
- ASCO: Testicular cancer history may indicate greater risk of developing prostate cancer
- Urine test could help to guide treatment of bladder cancer
- Multiple studies are exploring whether e-cigarettes help smokers quit or continue smoking
- Study identifies reasons for ibrutinib discontinuation in patients with chronic lymphocytic leukemia
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|